Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.80 |
| ▸ | AURKA | O14965 | 4/20 | 0.64 |
| ▸ | JAK2 | O60674 | 4/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.64 |
| ▸ | CDK2 | P24941 | 3/20 | 0.59 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | LYN | P07948 | 3/20 | 0.59 |
| ▸ | JAK3 | P52333 | 3/20 | 0.59 |
| ▸ | ITK | Q08881 | 3/20 | 0.59 |
| ▸ | PLK4 | O00444 | 2/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.59 |
| ▸ | PAK4 | O96013 | 2/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.59 |
| ▸ | PRKCG | P05129 | 2/20 | 0.59 |
| ▸ | INSR | P06213 | 2/20 | 0.59 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1196774 | 0.93 | SYK (0.69) | SYKAURKAJAK2AURKBEGFR | |
| SCHEMBL1196984 | 0.90 | SYK (0.74) | SYKAURKAJAK2AURKB | |
| SCHEMBL1198129 | 0.90 | SYK (0.78) | SYKAURKAJAK2AURKBCDK2 | |
| SCHEMBL28753633 | 0.89 | SYK (1.00) | SYKAURKAJAK2AURKBCDK2 | |
| SCHEMBL27631623 | 0.89 | SYK (1.00) | SYKAURKAJAK2AURKBCDK2 | |
| SCHEMBL1197542 | 0.88 | EGFR (0.67) | SYKAURKAJAK2AURKBCDK2 | |
| SCHEMBL1197903 | 0.88 | SYK (0.75) | SYKAURKAJAK2AURKBCDK2 | |
| SCHEMBL1197936 | 0.87 | SYK (0.78) | SYKAURKAJAK2AURKBCDK2 | |
| SCHEMBL4253356 | 0.86 | SYK (0.80) | SYKAURKAJAK2AURKBCDK2 | |
| SCHEMBL1196706 | 0.85 | CDK2 (0.77) | SYKAURKAJAK2AURKBCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834024-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | claimed |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | claimed |
| WO-2008118823-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | claimed |
| US-8299087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110027856-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7834024-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008118823-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | SYK 62/4885AURKA 751/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.